IART vs JNJ
IART: A global medical technology firm specializing in innovative surgical instrumentation, neurosurgical devices, and regenerative tissue repair solutions. JNJ: Johnson & Johnson is a global leader in innovative pharmaceuticals and advanced medical technology dedicated to addressing the world's most complex health challenges.
Side-by-side fundamentals
| Metric | IART | JNJ | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $19.53 | $256.35 | |
| Market cap as of 2026-08-03 | $1.5B | $617.8B | |
| P/E as of 2026-08-03 | n/a | 29.72 | |
| PEG as of 2026-08-03 | 1.40 | 3.39 | IART lower |
| Net margin as of 2026-08-03 | -30.1% | +21.5% | JNJ higher |
| Gross margin as of 2026-08-03 | +57.1% | +68.0% | JNJ higher |
| Operating margin as of 2026-08-03 | -28.4% | +25.7% | JNJ higher |
| ROE as of 2026-08-03 | -47.6% | +25.7% | JNJ higher |
| ROA as of 2026-08-03 | -13.7% | +10.6% | JNJ higher |
| Debt / equity as of 2026-08-03 | 1.79 | 0.58 | JNJ lower |
| Revenue growth (YoY) as of 2026-08-03 | +1.2% | +8.1% | JNJ higher |
| Revenue CAGR (3y) SEC XBRL | +1.6% | +6.2% | JNJ higher |
| Dividend yield as of 2026-08-03 | n/a | +2.1% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 1.22 | -0.04 | |
| 1-year return as of 2026-07-27 close | +49.0% | +55.6% | JNJ higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.